GB-115
Anxiolytic
No published human pharmacokinetics.
In short
- A dipeptide cholecystokinin-4 antagonist developed in Russia for anxiety.
- CCK-4 is a validated anxiety target — it reliably induces panic attacks in humans, so blocking it is a rational approach.
- Preclinical work reports anxiolytic and antidepressant-like effects without sedation.
- No published human clinical trial.
- Research compound only, not approved anywhere.
Structure
How it works
Cholecystokinin tetrapeptide (CCK-4) is one of the most reliable panicogens known — administering it to humans reliably provokes panic attacks, which makes it a standard experimental model in anxiety research.
GB-115 is a dipeptide designed to antagonise CCK receptors, blocking that signalling.
The target validity here is unusually good: unlike many anxiolytic mechanisms, the causal role of CCK signalling in inducing panic is directly demonstrated in humans.
What the research shows
Russian preclinical studies report anxiolytic and antidepressant-like effects in rodent models without the sedation and motor impairment of benzodiazepines.
No human clinical trial has been published.
It is worth noting that CCK antagonists as a class have been tried in humans before — several pharmaceutical programmes in the 1990s produced disappointing results in anxiety despite the strong target rationale.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Rodent — anxiolytic behavioural models | Low milligram-per-kilogram ranges; see source | intraperitoneal or oral | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported | 1–5 mg daily | oral or intranasal |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. No human study exists for this compound. The class history is relevant context: CCK antagonists with strong target rationale have previously failed to show anxiolytic benefit in human trials.
Handling and storage
Supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. The powder is comparatively stable; once reconstituted it is refrigerated and used within weeks. Track the date you reconstitute each vial — the Inventory section does this, and it is the difference between knowing a vial is three weeks old and guessing.
Oral or intranasal use is described in community practice. No route has been established in humans.
Side effects
No human safety data exists.
Preclinical work reports absence of sedation and motor impairment, which is the claimed advantage over benzodiazepines.
Community reports are sparse.
Combinations
No interaction data. Commonly combined with other anxiolytic peptides in community use, with no supporting evidence.
Research status
Developed at the Zakusov Institute of Pharmacology in Moscow, with published preclinical work.
The broader CCK antagonist literature is instructive and largely negative — this is a case where an excellent target rationale did not translate into clinical benefit for earlier compounds in the class.
Legal status
Not approved in any jurisdiction. Sold for research use only.
WADA status
Not specifically named on the Prohibited List. Falls under WADA class S0, which prohibits any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. Treat it as prohibited in sport.
Conclusion
GB-115 targets one of the best-validated anxiety mechanisms available — CCK-4 reliably causes panic in humans, so blocking it should work.
Earlier CCK antagonists with the same rationale went into human trials and disappointed. That history is the most useful thing to know here, and it is not in the marketing.
Sources
Track your own GB-115 protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.